Neomed back with new life sciences fund after long delay

Norwegian firm is active in the U.S. market and focuses on drugs undergoing clinical trials

1 November 2014•2 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.